Skip to main content
Clinical Trials/CTRI/2015/05/005751
CTRI/2015/05/005751
Recruiting
未知

Assessing the effects of transcranial direct current stimulation upon attentional measures in Lewy body dementia: a crossover trial.

Institute of Neurosciences Kolkata0 sites65 target enrollmentTBD

Overview

Phase
未知
Intervention
Not specified
Conditions
Health Condition 1: null- Dementia with Lewy bodies and Parkinsons Disease with Dementia
Sponsor
Institute of Neurosciences Kolkata
Enrollment
65
Status
Recruiting
Last Updated
4 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
4 years ago
Study Type
Interventional

Investigators

Eligibility Criteria

Inclusion Criteria

  • Participants are required to
  • Have been stable on anti\-cholinesterase, anti\-psychotic, memantine and/or anti\-parkinsonian medication for at least one month prior to participation.
  • Be able to provide written, informed consent
  • Be free from concurrent major psychiatric illness (e.g. major depression).
  • Be free from any severe physical illness or co\-morbidities which might limit their ability to fully participate in the study, or influence the effects of tDCS.

Exclusion Criteria

  • Participants will be unable to take part if any of the following apply:
  • If they have skin allergies or sensitivities to electrode gels, or any significant dermatological / scalp disease.
  • A history of excess alcohol intake.
  • A history of moderate\-to\-severe visual impairment secondary to glaucoma, cataract, or macular degeneration.
  • If they have metallic implants in the head/neck area or electronic implants of any kind (including pacemakers).
  • If they have a history of other neurological illness including, but not limited to stroke, intracerebral pathology and epilepsy.
  • If they are currently taking psychotropic or other medications which may significantly interfere with cognitive testing and tDCS efficacy (including high dose antipsychotics, dopamine agoinsts, sedative antidepressants, benzodiazepines except when low dose and used as hypnotics or treatment for REM\-sleep behaviour disorder and centrally acting anticholinergic drugs).

Outcomes

Primary Outcomes

Not specified

Similar Trials